HIV Combination Therapy Enhancing Antibody Recognition

The patent introduces CD4 binding site binding proteins as intermediary molecules that bridge the gap between antibodies and HIV-infected cells. These proteins bind to both the gp120 envelope protein and CD4 receptors, facilitating antibody recognition and binding to infected cells despite the virus's conformational changes. This intermediary mechanism resolves the contradiction by providing a stable binding interface that overcomes the harmful conformational variability of the envelope protein.

The patent employs fostemsavir and temsavir, which are prodrugs that undergo metabolic conversion to active forms. These compounds bind to the gp120 CD4 binding site, inducing conformational changes in the envelope protein that enhance antibody recognition. By changing the structural parameters of the gp160 envelope protein through drug-induced conformational shifts, the patent transforms the harmful conformational variability into a beneficial state that improves antibody binding and treatment effectiveness.

The patent merges multiple therapeutic agents (fostemsavir or temsavir, broadly neutralizing antibodies, and optionally integrase inhibitors) into a unified combination therapy regimen. This combining approach synergistically enhances antibody-dependent effector cell-mediated cytotoxicity by simultaneously targeting multiple viral mechanisms. The integration of attachment inhibitors with broadly neutralizing antibodies creates a coordinated attack that overcomes viral escape mechanisms, achieving superior productivity in clearing infected cells compared to single-agent therapies.

The combination therapy is segmented into distinct functional components: attachment inhibitors (fostemsavir/temsavir) that block viral entry, broadly neutralizing antibodies that recognize and neutralize the virus, and optional integrase inhibitors that prevent viral DNA integration. This segmentation allows each component to target specific viral processes, making the overall therapy more effective while maintaining manageable complexity through modular design. The segmented approach enables flexible dosing and combination strategies that optimize productivity without excessive complexity.